Literature DB >> 15195238

Immunity to influenza in older adults with chronic obstructive pulmonary disease.

Geoffrey J Gorse1, Theresa Z O'Connor, Frances K Newman, Mahendra D Mandava, Paul M Mendelman, Janet Wittes, Peter N Peduzzi.   

Abstract

BACKGROUND: Chronically ill older adults constitute a population vulnerable for complications associated with influenza. Study of their immunity to influenza virus may help design better strategies to stimulate protective immune responses.
METHODS: Immunogenicity of influenza vaccines and immune protection from natural influenza were assessed in older adults with chronic obstructive pulmonary disease as part of a vaccine efficacy trial. Subjects received either trivalent inactivated influenza virus vaccine (TVV) intramuscularly and trivalent live cold-adapted influenza virus vaccine (CAIV-T; n=1107) intranasally (inl) or TVV and placebo inl (P; n=1108).
RESULTS: In the subsets of study subjects assessed, serum hemagglutination inhibition (HAI) and nasal-wash antihemagglutinin (HA) immunoglobulin (Ig) A and IgG antibody levels and anti-influenza virus CD8(+) cytotoxic T lymphocyte activity increased after immunization. Mean postimmunization nasal-wash IgA antibody levels to influenza A H3/HA and B HA were statistically higher in the TVV+CAIV-T group (n=957) than in the TVV+P group (n=951). Postimmunization serum HAI and nasal-wash IgA antibodies to influenza A/H3N2 and B viruses were associated with a reduced relative risk for natural influenza infection.
CONCLUSIONS: TVV+CAIV-T appeared more immunogenic than TVV+P, but the observed difference may be clinically unimportant. Anti-influenza serum and nasal-wash antibodies were associated with immune protection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195238     DOI: 10.1086/421121

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  The influence of virus infections on the course of COPD.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

2.  Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers.

Authors:  Robert M Jacobson; Diane E Grill; Ann L Oberg; Pritish K Tosh; Inna G Ovsyannikova; Gregory A Poland
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Influenza vaccine responses in older adults.

Authors:  Janet E McElhaney
Journal:  Ageing Res Rev       Date:  2010-11-03       Impact factor: 10.895

Review 4.  Influenza vaccination in the elderly.

Authors:  Jan Smetana; Roman Chlibek; Jana Shaw; Miroslav Splino; Roman Prymula
Journal:  Hum Vaccin Immunother       Date:  2017-08-04       Impact factor: 3.452

5.  Safety, immunogenicity, and tolerability of three influenza vaccines in older adults: results of a randomized, controlled comparison.

Authors:  David W Scheifele; Shelly A McNeil; Brian J Ward; Marc Dionne; Curtis Cooper; Brenda Coleman; Mark Loeb; Ethan Rubinstein; Janet McElhaney; Todd Hatchette; Yan Li; Emanuele Montomoli; Amy Schneeberg; Julie A Bettinger; Scott A Halperin
Journal:  Hum Vaccin Immunother       Date:  2013-07-09       Impact factor: 3.452

Review 6.  Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review.

Authors:  S Sehatzadeh
Journal:  Ont Health Technol Assess Ser       Date:  2012-03-01

7.  Natural killer cells regulate T-cell proliferation during human parainfluenza virus type 3 infection.

Authors:  Cariosa M Noone; Elaine Paget; Ellen A Lewis; Marius R Loetscher; Robert W Newman; Patricia A Johnson
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

Review 8.  Vaccine strategies to enhance immune responses in the aged.

Authors:  Julie S Lefebvre; Laura Haynes
Journal:  Curr Opin Immunol       Date:  2013-06-10       Impact factor: 7.486

9.  Evaluating a surrogate endpoint at three levels, with application to vaccine development.

Authors:  Peter B Gilbert; Li Qin; Steven G Self
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

Review 10.  Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patients.

Authors:  Arnt-Ove Hovden; Rebecca Jane Cox; Lars Reinhardt Haaheim
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.